Medios (XTRA:ILM1) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ILM1 Stoklara Genel Bakış

Medios AG, iştirakleri ile birlikte, öncelikle Almanya'da özel farmasötik ilaçlar tedarik etmektedir.

ILM1 temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	2/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Trading at 57.5% below our estimate of its fair value

Earnings are forecast to grow 40.9% per year

Risk Analizi

Shareholders have been diluted in the past year

Medios AG Rakipler

HAEMATO

HMSE:HAEK

€80.5m

M1 Kliniken

XTRA:M12

€312.7m

RHÖN-KLINIKUM

XTRA:RHK

€843.4m

Stratec

XTRA:SBS

€528.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Medios
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	€15.56
52 Haftanın En Yüksek Seviyesi	€18.50
52 Haftanın En Düşük Seviyesi	€13.34
Beta	1.08
11 Aylık Değişim	-8.15%
3 Aylık Değişim	-3.35%
1 Yıllık Değişim	7.76%
33 Yıllık Değişim	-55.42%
5 Yıllık Değişim	-20.21%
Halka arzdan bu yana değişim	99.51%

Son Haberler & Güncellemeler

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

May 21

Recent updates

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

May 21

Are Medios' (ETR:ILM1) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17

Bullish: Analysts Just Made A Significant Upgrade To Their Medios AG (ETR:ILM1) Forecasts

Jan 21

What You Need To Know About Medios AG's (ETR:ILM1) Investor Composition

Jan 19

Is It Time To Consider Buying Medios AG (ETR:ILM1)?

Dec 24

Analysts Are Betting On Medios AG (ETR:ILM1) With A Big Upgrade This Week

Dec 09

The Medios (ETR:ILM1) Share Price Is Up 128% And Shareholders Are Boasting About It

Dec 08

Medios AG's (ETR:ILM1) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Nov 22

What Can We Make Of Medios AG’s (ETR:ILM1) High Return On Capital?

Jun 22

Hissedar Getirileri

	ILM1	DE Healthcare	DE Pazar
7D	-4.1%	2.6%	1.8%
1Y	7.8%	10.0%	13.8%

Getiri vs. Endüstri: ILM1 geçen yıl % 9.5 oranında getiri sağlayan German Healthcare sektörünün gerisinde kaldı.

Getiri vs Piyasa: ILM1 underperformed the German Market which returned 13.3% over the past year.

Fiyat Oynaklığı

Is ILM1's price volatile compared to industry and market?
ILM1 volatility
ILM1 Average Weekly Movement	5.3%
Healthcare Industry Average Movement	3.6%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: ILM1 has not had significant price volatility in the past 3 months.

Zaman İçindeki Volatilite: ILM1's weekly volatility (5%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2016	1,011	Matthias Gaertner	www.medios.ag

Medios AG, bağlı ortaklıkları ile birlikte, öncelikle Almanya'da özel farmasötik ilaçlar tedarik etmektedir. Şirket, Farmasötik Tedarik ve Hastaya Özel Tedaviler segmentleri aracılığıyla faaliyet göstermektedir. Farmasötik Tedarik segmenti onkoloji, nöroloji, otoimmünoloji, oftalmoloji, enfektiyoloji ve hemofili hastalıkları üzerine ürünler sunmaktadır.

Medios AG Temel Bilgiler Özeti

Medios'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ILM1 temel i̇stati̇sti̇kler
Piyasa değeri	€396.94m
Kazançlar(TTM)	€15.95m
Gelir(TTM)	€1.84b

24.9x

F/K Oranı

0.2x

P/S Oranı

ILM1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ILM1 gelir tablosu (TTM)
Gelir	€1.84b
Gelir Maliyeti	€1.72b
Brüt Kâr	€113.72m
Diğer Giderler	€97.77m
Kazançlar	€15.95m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 12, 2024

Hisse başına kazanç (EPS)	0.63
Brüt Marj	6.19%
Net Kâr Marjı	0.87%
Borç/Özkaynak Oranı	0.03%

ILM1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ILM1 Stoklara Genel Bakış

Ödüller

Risk Analizi

Medios AG Rakipler

HMSE:HAEK

€80.5m

XTRA:M12

€312.7m

XTRA:RHK

€843.4m

XTRA:SBS

€528.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 12% to €32.40

Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Recent updates

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 12% to €32.40

Medios AG (XTRA:ILM1) acquired Ceban B.V. from Bencis Capital Partners B.V.

Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There

First quarter 2024 earnings released: EPS: €0.17 (vs €0.20 in 1Q 2023)

Price target decreased by 14% to €34.60

Full year 2023 earnings: EPS and revenues miss analyst expectations

Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.

Investor sentiment improves as stock rises 21%

Medios AG (XTRA:ILM1) agreed to acquire Ceban B.V. from Bencis Capital Partners B.V. for € 259 million.

Medios AG, Annual General Meeting, Jun 26, 2024

Medios AG to Report Q2, 2024 Results on Aug 13, 2024

Price target decreased by 19% to €34.25

Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Medios AG to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.21 in 2Q 2022)

First quarter 2023 earnings released: EPS: €0.20 (vs €0.21 in 1Q 2022)

Full year 2022 earnings released: EPS: €0.77 (vs €0.37 in FY 2021)

Price target decreased by 7.4% to €42.40

Is Medios AG (ETR:ILM1) Trading At A 39% Discount?

Medios AG to Report First Half, 2023 Results on Aug 14, 2023

Investor sentiment improved over the past week

Is Medios (ETR:ILM1) Using Too Much Debt?

Medios AG (XTRA:ILM1) entered into a purchase agreement to acquire Blisterzentrum Baden-Württemberg Gmbh.

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations

Price target decreased to €45.80

Third quarter 2022 earnings: EPS exceeds analyst expectations

Is It Too Late To Consider Buying Medios AG (ETR:ILM1)?

Investor sentiment deteriorated over the past week

Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly

Is Now The Time To Look At Buying Medios AG (ETR:ILM1)?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Is Medios (ETR:ILM1) Using Too Much Debt?

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to €54.80

Investor sentiment deteriorated over the past week

Here's Why I Think Medios (ETR:ILM1) Is An Interesting Stock

What Does Medios AG's (ETR:ILM1) Share Price Indicate?

Medios AG Provides Earnings Guidance for the Fiscal Year 2022

Consensus forecasts updated

Medios (ETR:ILM1) Has A Pretty Healthy Balance Sheet

Medios AG (XTRA:ILM1) entered into an agreement to acquire NewCo Pharma GmbH.

Price target increased to €51.75

Third quarter 2021 earnings released: EPS €0.18 (vs €0.07 in 3Q 2020)

Is There Now An Opportunity In Medios AG (ETR:ILM1)?

Consensus forecasts updated

Second quarter 2021 earnings released: EPS €0.17 (vs €0.06 in 2Q 2020)

Medios AG's (ETR:ILM1) Intrinsic Value Is Potentially 35% Above Its Share Price

What Is Medios AG's (ETR:ILM1) Share Price Doing?

First quarter 2021 earnings released: EPS €0.15 (vs €0.15 in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: EPS €0.39 (vs €0.67 in FY 2019)

Medios AG Reiterates Revenue Guidance for the Financial Year 2021

New 90-day low: €34.80